ILIAS

Platform Technology

explor-img

EXPLOR®

Platform technology for
free-form cargo loading

EXosome engineering for Protein Loading via Optically
Reversible protein-protein interactions.

ILIAS’s EXPLOR® platform technology enables the intracellular delivery of
large-sized protein therapeutics such as antibodies by integrating a Reversible
protein-protein interaction module controlled by blue light. This allows
ILIAS to develop therapies that are highly effective for targeting key Intracellular
signaling pathways which were previously undruggable.

EXPLOR® uniquely enables cargo proteins to be loaded into exosomes in
free-form, whereas conventional exosome delivery technologies require the
molecule to be irreversibly anchored to the membrane, greatly limiting the
range and functionality of the cargo.

EXPLOR® provides highly efficient intracellular delivery of the functionally
active cargo proteins including signaling proteins, intracellular antibodies
(intrabodies), organelle-specific proteins, and/or gene-editing proteins.

creation-img

Cargo Loading
Process

  • A cargo protein-CRY2 (a part of the PPI module) complex
    and the CIBN (the counterpart of the PPI module)-
    membrane protein complex are stably expressed within
    the producing cells.
  • CRY2 and CIBN bind to each other under blue light during
    the cell culture to form a photoactivated complex and
    the resulting cargo protein will, in turn, be dragged into
    the exosomal lumen during endosomal maturation
    and exosome formation.
  • When the cargo-loaded exosomes are secreted and
    isolated from the culture medium, the blue light is turned-
    off to detach the cargo-CRY2 complex from the membrane.
    Therefore, the final exosome products contain free-form
    cargo proteins in their lumen.

Exo-Target®

Platform technology for active targeting

Exo-Target® technology enables increased tissue targeting and cargo
delivery efficiency using ILIAS exosomes' natural tropism or its surface
engineering technology.

Surface-modified exosomes have an improved inherent targeting
ability facilitating target-specific drug delivery.

One of pharmaceutical technology’s major challenges is the delivery
of protein drugs across biological barriers, such as the blood-brain
barrier (BBB). Certain exosomes are intrinsically able to cross the
biological barriers in human body. ILIAS’s Exo-Target® platform
technology dramatically improves cross-barrier protein delivery
through the engineering of exosome surfaces.

Through Exo-Target technology, ILIAS offers new treatment options for
indications with unmet medical needs due to the limited deliverability
of therapeutics to target organs and cells.